厄贝沙坦联合苯磺酸氨氯地平治疗糖尿病合并高血压的疗效观察

厄贝沙坦联合苯磺酸氨氯地平治疗糖尿病合并高血压的疗效观察

糖尿病和高血压是临床上发病率高的疾病。其主要特点是长期治疗、难治和长期治疗。当两种疾病共存时会进一步加重患者病情，提升治疗难度1数据和方法1.1餐后2hpg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg、pg纳入标准：空腹血糖（FPG）水平超过7mmol/L，餐后2h血糖（2hPG）水平超过11.1mmol/L，符合糖尿病诊断标准1.2组性别、年龄、成功率比较选取福鼎市医院2019年2月—2020年2月收治的糖尿病合并高血压患者92例，按照随机数字表法分为对照组与观察组，每组46例。对照组中男25例，女21例；年龄45～81岁，平均（63.6±2.8）岁；糖尿病病程3～13年，平均（8.3±1.6）年；高血压病程2～15年，平均（9.6±1.4）年。观察组中男27例，女19例；年龄45～83岁，平均（64.2±2.9）岁；糖尿病病程2～14年，平均（8.5±1.8）年；高血压病程3～16年，平均（9.8±1.6）年。2组性别、年龄、病程比较，差异无统计学意义（P>0.05），具有可比性。本研究符合福鼎市医院医学伦理委员会审核批准，患者及其家属均知情同意并签署知情同意书。1.3给药剂量调整2组均予以常规降糖治疗，即予以盐酸二甲双胍缓释片（生产厂家：天方药业有限公司，国药准字H20031225)0.5g/次，口服，2次/d；瑞格列奈片（生产厂家：江苏豪森药业股份有限公司，国药准字H20103637，规格：1mg)1mg/次，口服，3次/d。对照组予以苯磺酸氨氯地平（生产厂家：浙江京新药业股份有限公司，国药准字H20103356，规格：5mg）治疗，5mg/次，口服，1次/d，治疗1个月后坐位血压仍维持在140/90mmHg以上，则需要调整给药剂量，10mg/次，1次/d。观察组在对照组基础上予以厄贝沙坦（生产厂家：浙江华海药业股份有限公司，国药准字H20030016，规格：75mg）治疗，初始给药剂量为150mg/次，口服，1次/d，治疗1个月后坐位血压仍维持在140/90mmHg以上，则需要调整给药剂量，300mg/次，1次/d。2组均治疗2个月。1.4观察指标比较2组治疗前后血糖[空腹血糖（FPG）、餐后2h血糖（2hPG）、糖化血红蛋白（HbA1.5统计方法采用SPSS21.0统计学软件进行数据处理，计量资料以（2结果2.1血压和血压治疗前2组SBP、DBP、FPG、2hPG、HbA2.3副作用3两组患者临床治疗难度比较近年来，糖尿病、高血压患者数量明显增加，其中约有50%患者同时存在两种疾病，导致其临床治疗难度极大提升，降低患者生活质量，威胁患者生命安全本研究结果显示，治疗后观察组SBP、DBP、FPG、2hPG、HbA2.2两组c肽比较治疗前2组GA、C肽比较，差异无统计学意义（P>0.05）；治疗后观察组GA低于对照组，C肽高于对照组，差异有统计学意